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Abstract
Background: Interleukin (IL)-1b is a potent proinflammatory cytokine markedly overexpressed in the brains of
patients with Alzheimer’s disease (AD), and also involved in development of atherosclerosis and coronary artery
disease. Caspase-1 (CASP1), formerly called IL-1b converting enzyme (ICE), mediates the cleavage of the inactive
precursor of IL-1b into the biologically active form. CASP1 genetic variation (G+7/in6A, rs501192) has been
associated with susceptibility to myocardial infarction and cardiovascular death risk. We examined the contribution
of this gene to the susceptibility for AD.
Methods: We examined genetic variations of CASP1 by genotyping haplotype tagging SNPs (htSNPs) (rs501192,
rs556205 and rs530537) in a group of 628 Spanish AD cases and 722 controls.
Results: There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls
in the overall analysis or after stratification by age, gender or APOE ε4 allele.
Conclusion: Our negative findings in the Spanish population argue against the hypothesis that CASP1 genetic
variations are causally related to AD risk.
Background
A chronic inflammatory process might contribute to the
neurodegeneration associated with Alzheimer’s disease
(AD), by overexpression of cytokines, such as interleu-
kin-1 (IL-1), and other inflammatory molecules in acti-
vated microglia surrounding amyloid plaques [1].
Increased expression of IL-1 in AD has been implicated
in the formation of amyloid plaques and neurofibrillary
tangles, the spread of these neuropathological lesions
across cerebral cortical regions, and the accompanying
neuronal cell injury and loss [2]. The predominant b
isoform of IL-1 is generated from an inactive precursor
through the action of caspase-1 (CASP1), a cystein pro-
tease formerly called IL-1b converting enzyme (ICE),
and CASP1 expression appears to be significantly
increased in post-mortem brain tissue from patients
with AD [3-5]. In addition, CASP1 messenger RNA
expression has been closely associated with neurofibril-
lary tangle and, to a lesser extent, amyloid plaque
density [4]. Several studies have reported associations
between IL-1b genetic polymorphisms and AD, but
findings from different studies have been controversial
[6]. Although genetic markers of the CASP1 region
were not found associated to AD in recent genome-wide
association studies [7-10], Blankenberg et al. [11]
sequenced the CASP1 gene in a case-control study of
myocardial infarction (MI), and found that CASP1
genetic variation is associated with cardiovascular risk.
The present study investigated the genetic variability of
the CASP1 in relation to AD risk.
Methods
The study included 628 AD patients (65% women; mean
age at study 75.8 years; SD 8.1; range 61-109 years;
mean age at onset 72.7 years; SD 7.9; range 60-108
years) who met NINCDS/ADRDA criteria for probable
AD [12]. All AD cases were defined as sporadic because
their family history did not mention any first-degree
relative with dementia. AD patients were recruited from
the Departments of Neurology of University Hospital
“Marqués de Valdecilla” (Santander, Spain), and Hospi-
tal “La Paz” (Madrid, Spain). The large majority of
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referred by their general practitioner; few had been
admitted from hospital wards or nursing home facilities.
Control subjects were 722 unrelated individuals (65%
w o m e n ;m e a na g e7 8 . 7y e a r s ;S D9 . 3 ;r a n g e6 0 - 1 0 4
years) randomly selected from nursing homes. These
subjects had complete neurologic and medical examina-
tions that showed that they were free of significant ill-
ness and had Mini Mental State Examination scores of
28 or more, which were verified by at least one subse-
quent annual following-up assessment. The controls
arose from the same base population as the cases. The
AD and control samples were Caucasians originating
from a limited geographical area in northern Spain (San-
tander) and from the central area of Spain (Madrid).
Blood samples were taken after written informed con-
sent had been obtained from the subjects or their repre-
sentatives. The study was approved by the ethical
committees of the University Hospital “Marqués de Val-
decilla” and the Hospital “La Paz”. Genotyping of
CASP1 (rs501192 in intron 6, rs556205 in intron 7, and
rs530537 in intron 7) polymorphisms was performed by
a Taq-Man single-nucleotide-polymorphism assay
(Applied Biosystems, Warrington, Cheshire, UK) and an
ABI PRISM 7000 or 7900 HT sequence detection sys-
tems (Applied Biosystems). We used data from the Hap-
Map project http://www.hapmap.org to select the 3
htSNPs capturing 85% of CASP1 genetic variability in
Caucasians. SNPs were chosen among those with minor
allele frequencies ≥ 5% using Haploview v3.2 software
http://www.broad.mit.edu/mpg/haploview with an r
2
threshold of 0.8. APOE genotyping was performed by
amplification of the 4th exon of the APOE gene by PCR
with biotinylated primers, followed by reverse hybridiza-
tion on nitrocellulose strips, using the INNO-LIPA
ApoE assay (Innogenetics NV, Ghent, Belgium), or by
HhaI restriction analysis.
Hardy-Weinberg equilibrium (HWE) was calculated
for the 3 htSNPs genotypes in the control population
using Pearson’s c
2 statistics. We assessed pairwise link-
age disequilibrium (LD) between the 3 htSNPs by D’
and r
2 statistics. Haplotype reconstruction and their fre-
quencies in cases and controls were estimated by an
expectation-maximization algorithm. Pearson’s c
2 statis-
tics were performed to compare allele distribution of
the patients and control for each htSNP. Haplotype fre-
quencies were also assessed using Pearson’s c
2 using
Haploview 3.32 software http://www.broad.mit.edu/mpg/
haploview. Rare haplotypes (total frequency < 0.05) were
excluded from the analysis.
Results
In control groups, no significant deviations from Hardy-
Weinberg equilibrium were found for any of the 3 SNPs
(p-values ranging from 0.20 to 0.96). As shown in Table 1,
the distribution of the allele and genotype frequencies of
the CASP1 htSNPs did not differ significantly between AD
and control groups. The three CASP1 htSNPs were in
complete LD with each other (with r
2values close to 1.0)
forming one block, and therefore, they exhibited a pattern
of reduced haplotype diversity, with only four haplotypes
captured that did not differ between AD and control
groups (Table 2). Our analysis showed the expected asso-
ciation between the APOE ε4 allele and AD with an OR =
5.92 (95% CI = 4.60-7.62, p < 0.001) for carrying 1 or 2
copies of ε4 allele. There were no major differences in
allele, genotype or haplotype frequencies of CASP1 poly-
morphisms in our total sample stratified for age, gender or
APOE ε4 allele.
Discussion
Increasing evidence indicates that IL-1 is involved in
both development of atherosclerosis and cardiovascular
risk, and CASP1 might play a key role in the proathero-
genic effects mediated by IL-1b [11]. Blankenberg et al.
[11] investigated whether polymorphisms of the CASP1
gene might influence cardiovascular risk by analyzing
cases with myocardial infarction (MI) and controls in
British, French and German populations (n = 1774).
They sequenced all exons, up to 100 bp of exon/intron
junctions and up to 1 kb of 3’-a n d5 ’-flanking
sequences in CASP1, and found a block of 14 SNPs in
Table 1 Distribution of caspase-1 polymorphisms in
patients and controls
Caspase-1 polymorphisms Patients Controls
rs501192 (intron 6)
GG 436 (0.72) 519 (0.73)
GA 151 (0.25) 175 (0.25)
AA 18 (0.03) 15 (0.02)
Total 605 709
Allele frequency G/A 0.84/0.16 0.85/0.15
rs556205 (intron 7)
AA 514 (0.82) 606 (0.84)
AC 109 (0.17) 113 (0.16)
CC 5 (0.01) 3 (0.00)
Total 628 722
Allele frequency A/C 0.90/0.10 0.92/0.08
rs530537 (intron 7)
AA 159 (0.26) 200 (0.28)
AG 313 (0.52) 374 (0.52)
GG 134 (0.22) 144 (0.20)
Total 606 718
Allele frequency A/G 0.52/0.48 0.54/0.46
Figures in parentheses indicate frequencies; p-values > 0.05 for all allelic and
genotypic comparisons
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CASP1 (G+7/in6A, rs501192) A allele was associated
with a lower risk of MI in the British and German
populations, and the same allele exhibited a borderline
association with prospective cardiovascular death in the
German population. Moreover, the CASP1 haplotype
carrying the (G+7/in6A, rs501192) A allele was asso-
ciated with a lower gene expression, supporting the exis-
tence of a functional polymorphism within the CASP1
gene. All the 3 tagging SNPs analyzed in our study are
located in a single block that is the same haplotype
block as described by Blankenberg et al. [11] in their
European cohorts. Our main objective was to study the
CASP1 rs501192 in intron 6 (G+7/in6A) suggesting
CASP1 as a putative gene causing cardiovascular risk,
and in addition, we genotyped other SNPs in intron 7
(rs556205 and rs530537). We failed to observe any
allele, genotype or haplotype association with AD either
in the whole study or in APOE ε4-stratified subgroups
in the Spanish population.
Variation in the CASP1 gene has been associated with
cognitive function in elderly individuals with normal
cognition [13]: subjects carrying the CASP1 rs580253
(exon 6) A allele and rs554344 (3’-UTR) C allele had
significantly lower IL-1b production levels and per-
formed better on all executive function tests at baseline
and during follow-up compared to homozygous of the
wild-type allele. One might postulate that carriers of
these CASP1 genetic polymorphisms associated with
better memory have a higher “cognitive reserve”,a n d
consequently, would have a lower predisposition to AD.
Although both of these polymorphisms are in complete
linkage disequilibrium with our studied CASP1 genetic
variants, we did not find any genetic association with
AD risk. Contradictory association of a memory-related
genetic polymorphism with either healthy volunteers or
AD patients is already well known; for example, the
APOE ε4 allele is the only firmly established genetic
susceptibility factor for sporadic AD, but it has been
related to better memory in young, healthy volunteers
[14]. Moreover, healthy young, middle aged and elderly
carriers of the KIBRA rs17070145 T-allele exhibited a
clear advantage in delayed episodic recall compared to
individuals lacking the T-allele [15,16], but a further
study in a community AD population showed an asso-
ciation of the KIBRA rs17070145 T-allele with an
increase AD risk [17], thus resulting inconsistent with
previous findings in healthy subjects. Our negative
results are probably not due to insufficient statistical
power, because our sample size had enough power
(86%) to detect an odds ratio of 1.5 at disease allele fre-
quencies of 0.08. Because we only studied three htSNPs
capturing 85% of CASP1 genetic variability in Cauca-
sians, it might be argued that we have missed a
hypothetical disease locus, which would have been
detected by analysis of extended haplotypes. However,
the complete LD across the CASP1 region in our study
argues against this possibility; of note, two recent series
in other Caucasian populations [11,13] have also
detected a complete LD covering the whole gene
sequence. Despite supporting evidence for the biological
role of CASP1 in AD exists, according to our data
CASP1 genetic variation does not seem to be a risk fac-
tor for AD.
Conclusion
Our negative findings in the Spanish population argue
against the hypothesis that CASP1 genetic variations are
causally related to AD risk.
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Table 2 Haplotype association analysis between caspase-1
gene and AD
Haplotype
block
Haplotype
frequency
AD, control
frequency
p-value
GAA 0.531 0.521, 0.540 0.32
GAG 0.319 0.324, 0.315 0.60
ACG 0.088 0.094, 0.082 0.29
AAG 0.062 0.061, 0.063 0.83
Haplotype block consists of SNPs: rs501192, rs556205 and rs530537; rare
haplotypes (total frequency < 0.05) were excluded from the analysis; p-values
were not corrected for multiple comparisons.
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